# Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

Source: https://onco.cc/trials/nct06806033/  
OnCo record `nct06806033` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin in hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.

## Summary

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL is a phase 2 interventional study registered as NCT06806033 by Hoffmann-La Roche, with 130 participants planned, started 2025-03-05 and due to reach its primary completion in 2027-01-31. Interventions recorded: Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06806033
- Phase: 2
- Setting: A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab Monotherapy and Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- Sponsor: Hoffmann-La Roche
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06806033: https://clinicaltrials.gov/study/NCT06806033

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct06806033.json